Pharvaris N.V. Files September 2024 6-K Report

Ticker: PHVS · Form: 6-K · Filed: 2024-09-05T00:00:00.000Z

Sentiment: neutral

Topics: filing, 6-K, regulatory-update

TL;DR

Pharvaris N.V. (PHVS) filed a standard 6-K report for Sept 2024. No major news, just routine filings.

AI Summary

Pharvaris N.V. filed a Form 6-K on September 5, 2024, reporting for the month of September 2024. The company, previously known as Pharvaris, B.V., is incorporated in P7 and has its principal executive offices in Leiden, The Netherlands. This filing is a routine report for a foreign private issuer.

Why It Matters

This filing provides routine updates for investors and regulatory bodies regarding Pharvaris N.V.'s status as a foreign private issuer. It confirms their ongoing reporting obligations under the Securities Exchange Act of 1934.

Risk Assessment

Risk Level: low — This filing is a routine 6-K report and does not contain specific financial results, material events, or significant strategic updates that would typically impact risk levels.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers which provides information that the registrant makes or is required to make public pursuant to the laws of the registrant's home country or jurisdiction, or files or is required to file with a stock exchange on which the registrant's securities are traded.

When was Pharvaris N.V. previously known by another name?

Pharvaris N.V. was formerly known as Pharvaris, B.V., with a date of name change on 20201029.

What is the principal executive office address of Pharvaris N.V.?

The principal executive office is located at Emmy Noetherweg 2, 2333 BK Leiden, The Netherlands.

Does Pharvaris N.V. file annual reports under Form 20-F?

Yes, Pharvaris N.V. indicates by check mark that it files annual reports under cover of Form 20-F.

What is the SIC code for Pharvaris N.V.?

The Standard Industrial Classification (SIC) code for Pharvaris N.V. is 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0000950170-24-103729.txt : 20240905 0000950170-24-103729.hdr.sgml : 20240905 20240905065114 ACCESSION NUMBER: 0000950170-24-103729 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20240905 FILED AS OF DATE: 20240905 DATE AS OF CHANGE: 20240905 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharvaris N.V. CENTRAL INDEX KEY: 0001830487 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40010 FILM NUMBER: 241279902 BUSINESS ADDRESS: STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN STATE: P7 ZIP: 00000 BUSINESS PHONE: 31 (0)71 203 6410 MAIL ADDRESS: STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN STATE: P7 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: Pharvaris, B.V. DATE OF NAME CHANGE: 20201029 6-K 1 6-k_pr_september_5.htm 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2   2333 BK Leiden   The Netherlands (Address of principal executive office)   Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐   Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐   Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.   PHARVARIS N.V.   Pharvaris Provides Business Update and Expands Development Program for Deucrictibant   On September 5, 2024, Pharvaris N.V. (the “Company”) issued a press release titled “Pharvaris Provides Business Update and Expands Development Program for Deucrictibant” which announced the planned initiation of CHAPTER-3, the pivotal Phase 3 study of deucrictibant for the prophylactic treatment of HAE by the end of 2024, and its intention to pursue clinical development of deucrictibant in a newly named indication, acquired angioedema (AAE). Pharvaris Presents Deucrictibant Long-Term Extension Data for both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024   On September 5, 2024, the Company issued a press release titled “Pharvaris Presents Deucrictibant Long-Term Extension Data for both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024” highlighting certain presentations to be made on deucrictibant as a prophylactic and on-demand treatment of HAE attacks at the 7th Bradykinin Symposium, being held in Berlin from September 5-6, 2024

View on Read The Filing